NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
| Revenue (TTM) | $766.29M |
| Gross Profit (TTM) | $336.53M |
| EBITDA | $24.32M |
| Operating Margin | -4.84% |
| Return on Equity | -6.33% |
| Return on Assets | -1.89% |
| Revenue/Share (TTM) | $5.94 |
| Book Value | $6.14 |
| Price-to-Book | 3.00 |
| Price-to-Sales (TTM) | 3.29 |
| EV/Revenue | 3.473 |
| EV/EBITDA | 197.32 |
| Quarterly Earnings Growth (YoY) | 130.60% |
| Quarterly Revenue Growth (YoY) | 11.20% |
| Shares Outstanding | $128.47M |
| Float | $117.02M |
| % Insiders | 2.11% |
| % Institutions | 115.24% |
Volatility is currently expanding
NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.
Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NEO and any ticker you trade — then tracks every position and per-strategy win rate.
